RxDoctor Payments DataLook up a doctor →

Glenn Hamroff, MD

Cardiovascular Disease · Cortlandt Manor, NYNPI 1720081318

Payments from drug & device makers

$904,666in general payments, 2019–2025

Across 657 payments — averaging $1376.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$236K
  • Amgen$170K
  • Novartis$169K
  • Janssen Research & Development, LLC$138K
  • Johnson & Johnson$97K
  • AstraZeneca$45K
  • plus $51K from 35 others

What the payments were for

  • Consulting fees$3000%
  • Speaking & faculty fees$133,25882%
  • Travel & lodging$4,4923%
  • Food & beverage$24,00115%
  • Education$710%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$904,666 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$337,581
Medicare patients
1,205
Services billed
3,813

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban220$283,648
JardianceEmpagliflozin211$276,991
EliquisApixaban177$230,900
EntrestoSacubitril/Valsartan125$171,418
FarxigaDapagliflozin Propanediol50$69,978
Repatha SureclickEvolocumab41$59,937
MultaqDronedarone Hcl11$25,179
Metoprolol Succinate318$4,798
Atorvastatin Calcium297$4,540
Rosuvastatin Calcium240$4,405
Colchicine22$4,314
Valsartan90$3,555
Amlodipine Besylate253$2,344
Ezetimibe74$2,158
Torsemide66$2,148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$97,104$283,648220 claims
Boehringer IngelheimJardiance$12,877$276,991211 claims
PfizerEliquis$323$230,900177 claims
NovartisEntresto$169,127$171,418125 claims
AstraZenecaFarxiga$44,572$69,97850 claims
Sanofi-aventis U.S. LLCMultaq$14$25,17911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Cortlandt Manor

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →